A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension
Clinical Trial Grant
Administered By
Medicine, Rheumatology and Immunology
Awarded By
X4 Pharmaceuticals
Start Date
February 21, 2020
End Date
November 30, 2022
Administered By
Medicine, Rheumatology and Immunology
Awarded By
X4 Pharmaceuticals
Start Date
February 21, 2020
End Date
November 30, 2022